'The end' - or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants.
作者信息
Rahimi Farid, Darvishi Mohammad, Bezmin Abadi Amin Talebi
机构信息
Research School of Biology, The Australian National University, Ngunnawal & Ngambri Country, Canberra, ACT, 2600, Australia.
Infectious Diseases & Tropical Medicine Research Center (IDTMRC), Department of Aerospace & Subaquatic Medicine, AJA University of Medicinal Sciences, Tehran, 1411718541, Iran.
出版信息
Future Virol. 2023 Sep. doi: 10.2217/fvl-2023-0150. Epub 2023 Sep 19.
Abstract
摘要
相似文献
1
'The end' - or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants.“结束”——真的是这样吗？新型冠状病毒奥密克戎变异株EG.5和BA.2.86的出现。
Future Virol. 2023 Sep. doi: 10.2217/fvl-2023-0150. Epub 2023 Sep 19.
2
Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic.新型严重急性呼吸综合征冠状病毒2变种和亚变种：COVID-19大流行背景下的挑战与机遇
Environ Health Insights. 2022 Oct 20;16:11786302221129396. doi: 10.1177/11786302221129396. eCollection 2022.
3
Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.接种 COVID-19 mRNA 疫苗加强针对日本养老院队列中奥密克戎亚变种 BA.1 和 BA.5 的中和作用。
Vaccine. 2023 Mar 24;41(13):2234-2242. doi: 10.1016/j.vaccine.2023.02.068. Epub 2023 Feb 27.
4
Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.不同 SARS-CoV-2 奥密克戎亚变种在体外的复制和中和比较。
Animal Model Exp Med. 2023 Feb;6(1):51-56. doi: 10.1002/ame2.12302. Epub 2023 Feb 20.
5
A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.一种新冠DNA候选疫苗可诱导产生针对多种新冠病毒变种的广泛中和抗体，包括目前正在传播的奥密克戎BA.5、BF.7、BQ.1和XBB变种。
Vaccines (Basel). 2023 Mar 31;11(4):778. doi: 10.3390/vaccines11040778.
6
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.SARS-CoV-2 奥密克戎亚变体对泛冠状病毒融合抑制剂表现出不同的融合性，但敏感性相似。
Emerg Microbes Infect. 2023 Dec;12(1):2178241. doi: 10.1080/22221751.2023.2178241.
7
A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.基于三聚体 Spike 蛋白的四价 COVID-19 疫苗引发了针对 SARS-CoV-2 奥密克戎亚变体和其他变体的增强型广谱中和反应。
Sci China Life Sci. 2023 Aug;66(8):1818-1830. doi: 10.1007/s11427-022-2207-7. Epub 2022 Dec 30.
8
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.奥密克戎亚变体的中和敏感性、融合性和感染性。
Genome Med. 2022 Dec 29;14(1):146. doi: 10.1186/s13073-022-01151-6.
9
Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models.基于CV0501 mRNA的奥密克戎新冠疫苗在小动物模型中的免疫原性和有效性评估
Vaccines (Basel). 2023 Jan 31;11(2):318. doi: 10.3390/vaccines11020318.
10
Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay.使用多重流式细胞术检测试剂盒同时测量多种变异特异性 SARS-CoV-2 中和抗体。
Front Immunol. 2022 Nov 25;13:1039163. doi: 10.3389/fimmu.2022.1039163. eCollection 2022.
引用本文的文献
1
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.一种作为抗SARS-CoV-2变体疫苗候选物的病毒样结构（VLS）纳米递送系统的技术设计表征。
Hum Vaccin Immunother. 2025 Dec;21(1):2473183. doi: 10.1080/21645515.2025.2473183. Epub 2025 Mar 5.
2
and genetic polymorphisms as potential predictors of COVID-19 severity and outcome in females.以及基因多态性作为女性新冠病毒疾病严重程度和预后的潜在预测指标。
Front Med (Lausanne). 2024 Dec 18;11:1493815. doi: 10.3389/fmed.2024.1493815. eCollection 2024.
3
Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.用于通过接种疫苗、未接种疫苗和突破性感染 SARS-CoV-2 的病例建立血清学特征的多重中尺度发现免疫原性检测的验证和适用性评估
Vaccines (Basel). 2024 Apr 18;12(4):433. doi: 10.3390/vaccines12040433.
4
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial.四价蛋白疫苗SCTV01E-2针对SARS-CoV-2 EG.5亚变体的免疫原性：一项2期试验。
Vaccines (Basel). 2024 Feb 8;12(2):175. doi: 10.3390/vaccines12020175.
5
Development and Validation of a Robust and Interpretable Early Triaging Support System for Patients Hospitalized With COVID-19: Predictive Algorithm Modeling and Interpretation Study.开发和验证用于 COVID-19 住院患者的强大且可解释的早期分诊支持系统：预测算法建模和解释研究。
J Med Internet Res. 2024 Jan 11;26:e52134. doi: 10.2196/52134.
6
Virological Characteristics of Five SARS-CoV-2 Variants, Including Beta, Delta and Omicron BA.1, BA.2, BA.5.五种 SARS-CoV-2 变体（包括 Beta、Delta 和奥密克戎 BA.1、BA.2、BA.5）的病毒学特征。
Viruses. 2023 Dec 8;15(12):2394. doi: 10.3390/v15122394.
本文引用的文献
1
Covid-19: Infections climb globally as EG.5 variant gains ground.新冠疫情：随着EG.5变种毒株的传播，全球感染人数攀升。
BMJ. 2023 Aug 16;382:1900. doi: 10.1136/bmj.p1900.
2
Evolution of pathogen virulence: Studying the complex interplay of pathogen interactions, virulence and transmission helps us understand how they evolve and spread.病原体毒力的演变：研究病原体相互作用、毒力和传播的复杂相互作用有助于我们了解它们是如何演变和传播的。
EMBO Rep. 2023 Aug 3;24(8):e57611. doi: 10.15252/embr.202357611. Epub 2023 Jul 19.
3
Beta, Delta, and Omicron, Deadliest Among SARS-CoV-2 Variants: A Computational Repurposing Approach.贝塔、德尔塔和奥密克戎，新冠病毒变种中最致命的：一种计算性重新利用方法。
Evol Bioinform Online. 2023 Jul 11;19:11769343231182258. doi: 10.1177/11769343231182258. eCollection 2023.
4
End of COVID-19 emergencies sparks debate.新冠大流行紧急状态结束引发争论。
Science. 2023 May 12;380(6645):566-567. doi: 10.1126/science.adi6511. Epub 2023 May 11.
5
WHO declares end to COVID-19's emergency phase.世界卫生组织宣布新冠疫情紧急阶段结束。
Nature. 2023 May 5. doi: 10.1038/d41586-023-01559-z.
6
The evolution of SARS-CoV-2.严重急性呼吸综合征冠状病毒2的进化
Nat Rev Microbiol. 2023 Jun;21(6):361-379. doi: 10.1038/s41579-023-00878-2. Epub 2023 Apr 5.
7
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的德尔塔和奥密克戎变体：我们目前所了解的情况。
Vaccines (Basel). 2022 Nov 14;10(11):1926. doi: 10.3390/vaccines10111926.
8
Ending the covid-19 pandemic means helping countries to catch-up with vaccination, not giving up.终结新冠疫情意味着帮助各国追赶疫苗接种进度，而非放弃。
BMJ. 2022 Mar 24;376:o786. doi: 10.1136/bmj.o786.
9
On the origin and evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的起源与进化
Exp Mol Med. 2021 Apr;53(4):537-547. doi: 10.1038/s12276-021-00604-z. Epub 2021 Apr 16.
10
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.从武汉旅行回来后出现非典型肺炎症状的患者身上分离出的 2019 年新型人致病冠状病毒的基因组特征。
Emerg Microbes Infect. 2020 Jan 28;9(1):221-236. doi: 10.1080/22221751.2020.1719902. eCollection 2020.
Zotero 插件